Evidence map›Paper›PMID 32821092›Full record

Observational studyInternational journal of chronic obstructive pulmonary disease2020

Novel Respiratory Disability Score Predicts COPD Exacerbations and Mortality in the SPIROMICS Cohort.

Christopher B Cooper, Robert Paine, Jeffrey L Curtis, Richard E Kanner, Carlos H Martinez, Catherine A Meldrum, Russell Bowler, Wanda O'Neal, Eric A Hoffman, David Couper and 12 more

Registry-linked trialOpen access · goldAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in International journal of chronic obstructive pulmonary disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01969344 (Subpopulations and Intermediate Outcome Measures in COPD Study), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01969344 active not recruitingnot on this map

Subpopulations and Intermediate Outcome Measures in COPD Study

TypeobservationalSponsorUniversity of North Carolina, Chapel HillRan2010 to 2031Enrolled2,981ConditionsCOPD, Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 15 institutions in 1 country.

Christopher B CooperDepartments of Medicine and Physiology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.ORCID 0000-0002-6314-0903
Robert PaineSection of Pulmonary and Critical Care Medicine, Department of Veterans Affairs Medical Center, University of Utah, Salt Lake City, UT, USA.
Jeffrey L CurtisPulmonary and Critical Care Medicine Division, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA.ORCID 0000-0001-5191-4847
Richard E KannerSection of Pulmonary and Critical Care Medicine, Department of Veterans Affairs Medical Center, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0001-6915-599X
Carlos H MartinezPulmonary and Critical Care Medicine Division, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA.
Catherine A MeldrumPulmonary and Critical Care Medicine Division, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA.
Russell BowlerNational Jewish Health, University of Colorado School of Medicine, Denver, CO, USA.
Wanda O'NealUniversity of North Carolina Marisco Lung Institute, Chapel Hill, NC, USA.
Eric A HoffmanDepartment of Radiology, University of Iowa, Iowa City, IA, USA.ORCID 0000-0001-8456-9437
David CouperUniversity of North Carolina Marisco Lung Institute, Chapel Hill, NC, USA.ORCID 0000-0002-4313-9235
Miguel QuibreraUniversity of North Carolina Marisco Lung Institute, Chapel Hill, NC, USA.
Gerald CrinerDepartment of Pulmonary and Critical Care Medicine, Temple University, Philadelphia, PA, USA.
Mark T DransfieldDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0002-9207-1820
MeiLan K HanPulmonary and Critical Care Medicine Division, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA.
Nadia N HanselJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Jerry A KrishnanDepartment of Medicine, University of Illinois at Chicago, Chicago, IL, USA.ORCID 0000-0001-5525-4778
Stephen C LazarusDivision of Pulmonary and Critical Care Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Stephen P PetersWake Forest School of Medicine, Winston-Salem, NC, USA.ORCID 0000-0003-4176-7999
R Graham BarrDepartment of Medicine, Columbia University Medical Center, New York, NY, USA.
Fernando J MartinezJoan and Sanford I Weill Department of Medicine, Division of Pulmonary and Critical Care Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-2412-3182
Prescott G WoodruffDivision of Pulmonary and Critical Care Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
SPIROMICS investigators
Michigan Medicine · USUniversity of North Carolina at Chapel Hill · USUniversity of California, San Francisco · USUniversity of Utah · USColumbia University Irving Medical Center · USCornell University · USJohns Hopkins University · USNational Jewish Health · USTemple University · USUniversity of Alabama at Birmingham · USUniversity of California, Los Angeles · USUniversity of Illinois Chicago · USUniversity of Iowa · USVA Ann Arbor Healthcare System · USWake Forest University · US

Funding

SPIROMICS II: Biological underpinnings of COPD heterogeneity and progressionU01HL137880 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WOODRUFF, PRESCOTT G · 2017 to 2021
$27.9M
SPIROMICS GIC SupportU24HL141762 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COUPER, DAVID J, O'NEAL, WANDA K · 2018 to 2022
$7.2M
NHLBI NIH HHS HHSN268200900013CNHLBI NIH HHS HHSN268200900014CNHLBI NIH HHS HHSN268200900015CNHLBI NIH HHS HHSN268200900016CNHLBI NIH HHS HHSN268200900018CNHLBI NIH HHS HHSN268200900019CNHLBI NIH HHS HHSN268200900020CNHLBI NIH HHS U01 HL137880NHLBI NIH HHS U24 HL141762
6 · The paper itself

Abstract

Rationale: Some COPD patients develop extreme breathlessness, decreased exercise capacity and poor health status yet respiratory disability is poorly characterized as a distinct phenotype. Objective: To define respiratory disability in COPD based on available functional measures and to determine associations with risk for exacerbations and death. Methods: We analyzed baseline data from a multi-center observational study (SPIROMICS). This analysis includes 2332 participants (472 with severe COPD, 991 with mild/moderate COPD, 726 smokers without airflow obstruction and 143 non-smoking controls). Measurements: We defined respiratory disability by ≥4 of 7 criteria: mMRC dyspnea scale ≥3; Veterans Specific Activity Questionnaire <5; 6-minute walking distance <250 m; St George's Respiratory Questionnaire activity domain >60; COPD Assessment Test >20; fatigue (FACIT-F Trial Outcome Index) <50; SF-12 <20. Results: Using these criteria, respiratory disability was identified in 315 (13.5%) participants (52.1% female). Frequencies were severe COPD 34.5%; mild-moderate COPD 11.2%; smokers without obstruction 5.2% and never-smokers 2.1%. Compared with others, participants with disability had more emphysema (13.2 vs. 6.6%) and air-trapping (37.0 vs. 21.6%) on HRCT (P<0.0001). Using principal components analysis to derive a disability score, two factors explained 71% of variance, and a cut point -1.0 reliably identified disability. This disability score independently predicted future exacerbations (ß=0.34; CI 0.12, 0.64; P=0.003) and death (HR 2.97; CI 1.54, 5.75; P=0.001). Thus, participants with disability by this criterion had almost three times greater mortality compared to those without disability. Conclusion: Our novel SPIROMICS respiratory disability score in COPD was associated with worse airflow obstruction as well as airway wall thickening, lung parenchymal destruction and certain inflammatory biomarkers. The disability score also proved to be an independent predictor of future exacerbations and death. These findings validate disability as an important phenotype in the spectrum of COPD.

Indexed as

Pulmonary Disease, Chronic ObstructiveCohort StudiesDyspneaFemaleHumansLungMaleSurveys and Questionnairesdisabilityexacerbation ratefrailtymortalitySPIROMICS

Identifiers

PMID32821092
PMCPMC7417644
OpenAlexW3046699176

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.